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Abstract: Preclinical and clinical studies suggest that many food molecules could interact with drug 
transporters and metabolizing enzymes through different mechanisms, which are predictive of 
what would be observed clinically. Given the recent incorporation of dietary modifications or 
supplements in traditional medicine, an increase in potential food-drug interactions has also 
appeared. The objective of this article is to review data regarding the influence of food on drug 
efficacy. Data from Google Scholar, PubMed, and Scopus databases was reviewed for publications 
on pharmaceutical, pharmacokinetic, and pharmacodynamic mechanisms. The following online 
resources were used to integrate functional and bioinformatic results: FooDB, Phenol-Explorer, Dr. 
Duke's Phytochemical and Ethnobotanical Databases, DrugBank, UniProt, and IUPHAR/BPS Guide 
to Pharmacology. A wide range of food compounds were shown to interact with proteins involved 
in drug pharmacokinetic/pharmacodynamic profiles, starting from drug oral bioavailability to 
enteric/hepatic transport and metabolism, blood transport, and systemic transport/metabolism. 
Knowledge of any food components that may interfere with drug efficacy is essential, and would 
provide a link for obtaining a holistic view for cancer, cardiovascular, musculoskeletal, or 
neurological therapies. However, preclinical interaction may be irrelevant to clinical interaction, and 
health professionals should be aware of the limitations if they intend to optimize the therapeutic 
effects of drugs. 
Keywords: food-drug interactions; herb-drug interactions; pharmacologic processes; dietary 
supplements; nutraceutical; precision medicine 
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1. Introduction 
Oral drug administration is easy, cost-effective, and often preferred by patients, because they 
are able to take medicine without assistance or a dedicated delivery device, therefore assuming 
pharmacological therapy independently and at home. However, drug efficacy may be modified by 
meals consumed concomitantly, as food matrices and bioactive compounds might interfere at 
different phases of the pharmacokinetic process. Specifically, food-drug interactions in the absorption 
phase of orally administered drugs are investigated by studies of food-effect bioavailability (BA) and 
fed bioequivalence (BE) [1], and proper information about the correct way of drug consumption 
should always be conveyed to the patient. However, the recent and increasing use of traditional 
medicine along with complementary and alternative medicine (CAM) approaches, such as dietary 
modifications and dietary supplements, overcomes the concepts of fed or fasting drug 
administration, as patients are exposed to novel foods and supplements that contain various food 
bioactive compounds, such as nutraceuticals or phytochemicals [2]. For instance, food molecules may 
interfere with proteins involved in drug metabolism, which in turn cause variable and limited drug 
bioavailability [3–5], even though precise and comprehensive reviews of practical implications are 
mostly unseen. 
Recent preclinical and clinical studies have suggested that many food molecules could interact 
with drug transporters and metabolizing enzymes through different mechanisms, which are 
predictive of what would be observed clinically. The lack of information could be the basis of some 
cases of pharmacological inefficacy [6]. Other effects of these overlooked food-drug interactions 
could be associated with unstable control of symptoms [7], or increased rates of side effects or 
occurrence of unexpected adverse events [8], specifically for patients suffering from chronic diseases 
that require the use of multiple drugs. Advertised effects of food supplements can attract misguided 
individuals who face a needless waste of money or unsafe interactions [9]. CAM approaches are often 
abused by patients who seek alternative therapies, possibly augmenting the risk of side effects and 
pharmacological opposition [10]. Given this usage trend and variability in individual 
pharmacological therapies and dietary habits, an increase in potential food-drug interactions has 
recently appeared. Historical recommendations for drug administration primarily concern fed or 
fasting conditions, alcohol, caffeine, grapefruit juice (Citrus x paradisi M.), and St. John's wort 
(Hypericum perforatum L.). This review aims at pointing out the most relevant data concerning food 
influence on drug efficacy, by classifying the mechanisms through which food bioactive compounds 
may interfere with drug pharmacokinetic/pharmacodynamic (PK/PD) profiles. Furthermore, a 
panorama of existing preclinical, clinical, and bioinformatic evidence is provided. 
Methodology of the Review 
Data from Google Scholar, PubMed, and Scopus databases were reviewed, focusing on 
publications regarding pharmaceutical, pharmacokinetic, and pharmacodynamic mechanisms 
through which food components may interact with drug metabolism. The search considered in vitro 
and in vivo preclinical studies, clinical trials, and bioinformatic approaches. The presence of relevant 
food bioactive compounds in foods was integrated from the most authoritative online databases 
FooDB v.1.0 (http://foodb.ca/), Phenol-Explorer v.3.6 (http://phenol-explorer.eu/), and Dr. Duke's 
Phytochemical and Ethnobotanical Databases v.1.9.12.6-Beta (https://phytochem.nal.usda.gov/). 
Targets, such as transporters, enzymes, and receptors were characterized for bioinformatic and 
functional information from DrugBank v.5.1.1 (https://www.drugbank.ca/), UniProt 
(https://www.uniprot.org/), and IUPHAR/BPS Guide to Pharmacology v.2018.4 
(http://www.guidetopharmacology.org/). Unique bioactivity data of food molecules against drug 
target proteins was reviewed from the food-drug interactome map [11], managing to link the 
chemical space of diverse food molecules to drug target space. The cytochrome P450 drug interaction 
table of Indiana University School of Medicine (http://medicine.iupui.edu/) was used to integrate 
literature results relating to pharmacokinetic interactions. 
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2. Types of Food-drug Interactions 
Food-drug interactions can be broadly classified as occurring at (i) pharmaceutical 
(compatibility, solubility, stability), (ii) pharmacokinetic (absorption, distribution, metabolism, 
excretion), or (iii) pharmacodynamic (clinical effect) level, and are the result of physical or chemical 
exchanges between a food molecule and a drug. More precisely, another classification defined four 
types of food-drug interactions according to the distinction between pre-systemic and post-systemic 
phases [12]: 
 Type I interactions (pharmaceutical), which refer to ex vivo bio-inactivations that usually occur 
in the delivery device with reactions of hydrolysis, oxidation, neutralization, precipitation, or 
complexation. 
 Type II interactions, which affect the function of an enzyme (subtype A interactions, 
pharmacokinetic) or a transport mechanism (subtype B interactions, pharmacokinetic) before 
systemic circulation, in turn altering the absorption and bioavailability of oral or enteral 
administrations. Complexation, binding, or other deactivations may occur in the gastrointestinal 
tract (type C interactions, pharmaceutical). 
 Type III interactions (pharmacokinetic), which occur after entrance into systemic circulation and 
involve changes in tissues distribution, penetration, or metabolism. 
 Type IV interactions (pharmacokinetic), which denote affections in drug or food component 
clearance because of influences upon renal or enterohepatic excretion. 
Although more accurate, this latter classification omits pharmacodynamic interactions, which 
could be considered the indirect result of previous pharmaceutical or pharmacokinetic interactions 
that could ultimately alter the clinical effect of the drug. However, recent direct pharmacodynamic 
interactions were discovered through bioinformatic approaches, as food molecules were shown to 
possibly act against same drug targets and compete for target-binding. Food-drug interactions 
happen continuously and daily, but they are considered relevant only if they predispose to treatment 
failure or adverse events, which are still hard to associate with food interference. 
3. Pharmaceutical Interactions 
Pharmaceutical interactions comprise types I and IIC food-drug interactions, and are due to the 
fact that the food matrix might directly react with medicines or indirectly alter their absorption by 
changing the gastrointestinal milieu [13]. These types of interactions have primarily been a matter of 
concern in intensive care units for many years, where the combination of multiple drugs is common, 
and therefore decisions of proper route, dose, and timing of drug administrations are always made 
considering food interferences. Knowledge of compatibility, solubility, and stability is necessary to 
avoid alterations upstream of the pharmacological response. When considering pharmaceutical 
interactions, drugs are classified according the Biopharmaceutics Classification System (BCS), which 
considers aqueous solubility and intestinal permeability [14]. When combined with the dissolution 
of the drug product, drugs are classified as follows: (i) class I (high solubility-high permeability), (ii) 
class II (low solubility-high permeability), (ii) class III (high solubility-low permeability), and (iv) 
class IV (low solubility-low permeability). Food matrix effects on drug bioavailability are least likely 
to occur with rapidly dissolving class I drugs, because their absorption is usually pH- and site-
independent, and thus insensitive to differences in dissolution. However, food can indeed influence 
drug bioavailability when there is a high first-pass effect, extensive adsorption, complexation, or 
instability of the drug substance in the gastrointestinal tract, thus affecting the plasma maximum 
concentration of the drug (Cmax) and time to reach plasma maximum concentration (Tmax) by delaying 
gastric emptying and prolonging intestinal transit time. Concerning class II, III, and IV drug products, 
food, but also alcohol, is most likely to impact the in vivo dissolution or the absorption [1]. The BCS 
was reported to be integrated by the Biopharmaceutics Drug Disposition Classification System 
(BDDCS), which replaced the permeability criteria with the metabolism extent, with class I and II 
drugs being high permeable and class III and IV drugs being low permeable [13]. For instance, high 
permeability drugs [14], and also food components, are caffeine (coffee, energy drinks, sugary or 
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sugar-free drinks) and theophylline (cocoa, tea). Type I interactions are far more common with drugs 
and nutrients administered intravenously, as they may be mixed in the delivery device and form 
precipitates for physical incompatibility. Conversely, type IIC interactions can be considered part of 
enteral or oral feeding practice, where chelation between divalent and trivalent cations with drugs 
may occur [12]. Also, polyvalent cations in milk and dairy products were reported to interact with 
some tetracyclines [15] and fluoroquinolones [16]. Indeed, it is important to consider the 
physiochemical milieu of the gastrointestinal tract, as food consumption delays gastric emptying, 
stimulates bile flow, changes gastrointestinal pH, increases splanchnic blood flow, changes luminal 
metabolism of a drug substance, and physically or chemically interacts with a dosage form or a drug 
substance [1]. For instance, chronic administration in rats of Capsicum annuum L. reduced 
acetylsalicylic acid, likely as a consequence of capsaicin (Capsicum genum) gastrointestinal effects 
[17]. 
Fed conditions state that the drug product is administered 30 min after start of the recommended 
meal, and with a glass of water. No food is allowed for at least 4 h post-dose. Water can be allowed 
as desired except for 1 h before and after drug administration [1]. Effect of meal per os can be 
considered a type IIC interaction, with an indirect influence on the drug rate and extent of absorption. 
Meals mainly affect drug absorption by way of Tmax, but do not necessarily lead to a reduction of the 
area under the concentration-curve (AUC) [12]. If food delays the onset of drug action, the efficacy 
might not be affected, despite differences in the pharmacokinetic profile. Conversely, the efficacy of 
some drugs, such as sildenafil, may be Cmax-driven and the delay of Tmax due to the concomitant food 
consumption can affect clinical efficacy. In fact, when food intake causes a significant change in the 
AUC of a drug, the overall amount absorbed could be reduced and would cause a far more clinical 
effect. An exception appears to be levodopa and its interactions with dietary proteins: although a 
delayed absorption in the presence of food, with no changes in AUC as compared to without food, 
clinical efficacy was deeply affected [18]. The transit time of a drug product and its luminal 
dissolution, together with its permeability and systemic availability, are greatly affected when the 
administration occurs shortly after a meal is ingested. Dietary proteins were found to interact with 
the antiepileptic agent phenytoin, thus causing a reduced absorption of the drug [19]. Dietary fiber 
may act as a physical barrier and prevent drug contact with the gastrointestinal mucosa, but it can 
also directly adsorb drug molecules [13]. Soluble fibers, such as pectin, glucomannan, psyllium, and 
guar gum, which are able to form highly viscous solutions in water, were reported to interfere with 
the absorption of various medications, as well as insoluble components, such as cellulose or bran [20]. 
High-energy and high-fat meals are more likely to affect the gastrointestinal physiology and to 
facilitate intestinal uptake of the more lipophilic drugs [1], and therefore they are considered as test 
meals for food-effect studies. In general, high-fat meals increase the absorption of hydrophobic drugs 
through enhanced solubilization, but can conversely stimulate the formation of drug-bile micelles 
and decrease hydrophilic drug absorption [13]. The absorption of the antiretroviral azatanavir 
showed an increased AUC when administered with food [21]. For instance, a recommended meal for 
tests would comprise two eggs fried in butter, two strips of bacon, two slices of toast with butter, one 
hundred grams of hash brown potatoes, and about 220 grams of whole milk [1]. Food lipids promote 
the release of cholecystokinin, which slows gastrointestinal motility and increases the contact time 
between the drug molecules and the intestinal epithelial tissues. Indeed, decreased gastrointestinal 
motility increases the contact time between the drug and epithelial tissue, thus potentially allowing 
more complete absorption into the portal vein [12]. The content of fat in meals should be accounted 
for oral chemotherapeutics [22]. Conversely, significant decreased gastrointestinal tone may cause 
toxicities because of a more complete absorption, whereas decreased motility may augment the risk 
of clinical inefficacy [12]. Serotonin pathways in the gastrointestinal tract promote motility and foods 
rich in serotonin may shorten physical contact time [2]. Administration under fasting conditions 
refers to the consumption of the medicine with a glass of water after an overnight fast of at least 10 
h. No food is allowed for at least 4 h post-dose, and water intake is allowed as desired except for 1 h 
before and after drug administration. 
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4. Pharmacokinetic Interactions 
Pharmacokinetic interactions are types IIA, IIB, III, and IV. Absorption and excretion 
mechanisms, together with tissue metabolism, depend on transporters and metabolizing enzymes. 
Transepithelial and transendothelial fluxes comprise transporters across the intestine, the liver, the 
kidney, and brain capillaries. In general, transporters that exert a major role in xenobiotic metabolism 
include two major superfamilies: the solute carrier (SLC) superfamily, which comprises forty-eight 
subclasses, and the ATP-binding cassette (ABC) superfamily, which includes seven subclasses. The 
SLC superfamily encompasses a variety of transporters, such as the organic anion transporters (OAT) 
and the organic cation transporters (OCT) of family 22. Formerly known as SLC family 21, the SLCO 
family is now grouped as the organic anion transporting polypeptides (OATPs). ABC proteins are 
primary ATP-dependent and comprise seven subclasses (from ABCA to ABCG). They are known to 
be involved in the excretion of different molecules, thus decreasing the bioavailability of certain 
compounds. The purpose of these efflux transporters is believed to minimize host xenobiotic 
exposure, prevent the saturation of cytoplasmic enzymes, or provide repeated opportunities to 
metabolize the xenobiotic compound [12]. Active efflux proteins include the multidrug resistance 
protein 1 (MDR1), also known as P-glycoprotein 1 (P-gp), of family ABCB1, the canalicular multidrug 
resistance-associated protein 1 and 2 (MRP1 and MRP2) of family ABCC1 and ABCC2, respectively, 
and the breast cancer resistance protein (BCRP) of family ABCG2. MDR1 seems to manage preferably 
amphipathic cationic compounds and is representative among efflux transporters, thus tightly 
regulating how quickly and how much drug can reach the metabolizing enzymes located in the 
endoplasmic reticulum. 
Xenobiotic metabolism is primarily accounted for by the highly polymorphic and inter-
individual variable cytochrome P450 enzyme families (CYP450), whose activities are majorly 
concentrated in the liver and in the enteric villous tips from the duodenum to the distal jejunum, with 
a minor role for extrahepatic enzymes located in the lungs and brain. They are an extensive family of 
hem-containing monooxygenases with a huge range of both endogenous and exogenous substrates, 
and primarily mediate phase I reactions, such as oxidation, reduction, and hydrolysis. Single CYP 
has the capacity to metabolize structurally diverse molecules, and a single substrate can be 
metabolized by different CYPs. Additionally, CYPs exert their catalytic activity at different regions 
on the molecule, giving the promiscuous substrate binding sites in the enzyme. In humans, three 
families of CYPs mostly involved in xenobiotic metabolism are the CYP1, CYP2, and CYP3. CYP3A4 
is representative among these enzymes, as it metabolizes a vast range of drugs in the liver, such as 
benzodiazepines, antidepressants, chemotherapeutic agents, and calcium channel blockers. Phase I 
reactions are also mediated by flavin-containing monooxygenases (FMO). Other oxidative reactions 
are catalyzed by alcohol dehydrogenases (ADH) and monoamine oxidases (MAO), respectively 
localized in the cytosol and on the mitochondrial outer membrane of the liver. Phase II reactions 
involve other metabolizing or conjugating enzymes, such as sulfotransferases (SULT), UDP-
glucuronosyltransferases (UGT), NAD(P)H:quinone oxidoreductase (DT-diaphorase), epoxide 
hydrolases (EPH), glutathione S-transferases (GST) and N-acetyltransferases (NAT), all of which 
produce end products more readily excreted. The conjugation reactions, by promoting excretion in 
the bile and/or the urine, affect detoxification. 
For better comprehension, pharmacokinetic interactions can be divided into pre-systemic and 
post-systemic food-drug interactions. The pre-systemic involves the first-pass metabolism of 
xenobiotics, which takes place first in the intestine and then in the liver after transit in the 
bloodstream, with the stomach accounting for a minor role. Post-systemic concerns food-drug 
interactions that occur after entrance into the systemic circulation, comprising tissue penetration and 
metabolism. Eventually, proteins targeted by food bioactive compounds at the pre-systemic and post-
systemic levels may overlap, as they can be expressed in multiple cells. 
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4.1. Pre-Systemic Interactions 
Absorption mechanisms across intestinal epithelial cells is vectoral in nature, as cells are 
polarized and organized in monolayers. OATPs and SLC transporters primarily carry out both gut 
and hepatic absorption of amphipathic organic anions and hydrophilic organic cations, respectively, 
accounting for the uptake of many food components and drugs. Enteric ABC proteins excrete 
xenobiotics back into the gut lumen. Drug resistance may occur because of a decreased uptake or an 
enhanced efflux of drugs, which is associated to hydrophobic anticancer refractoriness because of the 
overexpression of these transporters in tumor cells. On the apical side of intestinal epithelia, efflux 
proteins include the MDR1, the MRP2, and the BCRP. MRP3 of family ABCC3 is expressed on the 
basolateral membrane of epithelial cells. ABCs are also located on the blood-facing membrane of 
hepatocytes and on the bile canalicular membrane where they export compounds into the bile. 
Hepatic drug uptake, followed by metabolism and excretion, is the major determinant of the pre-
systemic clearance since liver activity ultimately determines systemic blood levels. Nevertheless, the 
inhibition of these influx and efflux transporters by bioactive food compounds may alter the 
synchronization of the enteric/hepatic transport-metabolic systems, thus leading to a significant 
change in a drug oral bioavailability and a relevant food-drug interaction. Of note, an atypical food-
drug interaction was reported [23], with black pepper, red pepper, and ginger increasing microvilli 
length and perimeter in animals, thus potentially facilitating the overall absorption capacity of the 
small intestine. 
4.1.1. Food Interference with Enteric and Hepatic Transport 
Grapefruit is a classic example of both drug transportation and CYP450 drug oxidation 
modulator, as it was stated to exert an opposite effect on xenobiotic transporters and metabolizing 
enzymes. It was reported to inhibit drug absorption catalyzed by the intestinal OATP1A2, thus 
lowering plasma concentration of substrates [24]. In particular, naringin of grapefruit and hesperidin 
of Citrus spp. proved in vitro to inhibit human OATP1A2, and naringin showed to be clinically 
relevant [25]. It has also been reported that the major constituents of grapefruit, as well as orange 
(Citrus x sinensis L.) juice, significantly inhibited the OATP2B1 function in vitro [26]. Concomitant 
administration of Seville orange (Citrus x aurantium L.) or apple juice with fexofenadine decreased 
drug absorption in rats, likely acting on OATPs [27]. In fact, significant inhibition of OATP drug 
transporters was observed not only for grapefruit and orange juice, but also for apple juice [28]. In 
particular, apple showed to inhibit non-human OATP2B1 in vitro [29], easily attributable to the 
similar composition of flavonoids between grapefruit, orange, and apple. In a clinical trial, grapefruit 
juice at a commonly consumed volume diminished oral bioavailability of a drug substrate of the 
intestinal OATP1A2, likely acting as inhibitor [30]. A reduction of fexofenadine AUC and Cmax was 
observed in humans after consumption of orange and apple juice [31]. Apigenin (marjoram—
Origanum majorana L., parsley—Petroselinum crispum L., Chinese cabbage, ginkgo—Ginkgo biloba L.), 
kaempferol (capers, cumin—Cuminum cyminum L., caraway—Carum carvi L., dill—Anethum 
graveolens L., common pea, tarragon—Artemisia dracunculus L., cabbage—Brassica oleracea var. 
Capitate L., garden cress—Lepidium sativum L., ginkgo), and quercetin (onion, Chinese cabbage, 
capers, black elderberry, ginkgo) competitively inhibited enteric OATP1A2 and OATP2B1 in vitro 
[32]. The hepatic transporters OATP1B3 and OATP2B1, which are involved in drug uptake on the 
basolateral membrane, were inhibited in vitro by the various flavonoids from ginkgo (apigenin, 
kaempferol, quercetin) and from grapefruit (naringenin, naringin, rutin—quercetin glycoside). No 
effect on the hepatic OCT1 was found [33]. Bioinformatic evidences confirmed the bioactivity of 
naringenin, naringin, and quercetin against OATP1B1, OATP1B3, and OATP2B1 [11]. Same 
transporters can be targeted by daidzein (soy bean, soy products), genistein (lima bean—Phaseolus 
lunatus L., soy bean and products), and glycyrrhizin (liquorice) [11]. Moreover, caffeine acts not only 
against OCT1, but also OATP1B1, OATP1B3, and OATP2B1 [11]. Data is summarized in Table 1. 
MDR1 is expressed in tissues that are exposed to xenobiotics, such as the apical surface of jejunal 
and colonic cells, but also in the canalicular surface of hepatocytes, with both MDR1 and MRP2 
governing active biliary excretion [34]. Grapefruit and orange juices inhibited in vitro the intestinal 
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MDR1 and MRP2 [35], potentially counterbalancing the action on OATPs. Intestinal MDR1 activity 
was inhibited in another in vitro study by extracts of bitter melon, soybean, dokudami and Welsh 
onion, with authors attributing to 1-monopalmitin of bitter melon the most potent inhibition [36]. 
Diosmin increased the apical-to-basal transport and decreased the efflux transport in human 
intestinal cells in vitro [37], thus supporting the inhibitory action on MDR1 by Citrus spp. 
Methoxyflavones of orange and tangerine (Citrus reticulata B.), such as tangeretin, were suggested to 
be responsible for the specific inhibition of intestinal MDR1 in vitro [38]. Bergamottin, tangeretin, and 
nobiletin were shown to potently inhibit BCRP in a concentration-dependent manner [39], and. in 
particular. nobiletin showed an inhibitory effect on MDR1 and MRP1 [40]. Sulforaphane from 
cruciferous vegetables, such as broccoli (Brassica oleracea var. Italica), cauliflower (Brassica oleracea var. 
Botrytis), radish (Raphanus raphanistrum subsp. sativus), but also watercress (Nasturtium officinale 
W.T.A.), is an isothiocyanate forming from the hydrolysis of glucosinolates by the action of the co-
existing, but physically segregated, enzyme myrosinase. Sulforaphane increased intestinal protein 
levels of MRP1 and MRP2 in vitro [41]. Long-term feeding with ginseng (Panax L.) induced the 
expression of intestinal MDR1 expression in rats, thus decreasing the bioavailability of fexofenadine 
[42]. Sesamin of sesame, ginkgolic acid of ginkgo, and glycyrrhetinic acid and glabridin of liquorice, 
inhibited MDR1 of cells in vitro, with glycyrrhetinic acid inhibiting also the function of MRP1 [43]. 
In a clinical trial, repeated ingestion, but not single oral dose, of ginkgo was able to increase Cmax and 
AUC of talinolol, likely due to the inhibition mechanism of intestinal MDR1 and MRP2 that 
overwhelmed the inhibition of intestinal OATPs [44]. Piperine of Piper genus inhibited human MDR1 
[45]. Rosemary and common sage (Salvia officinalis L.) phytochemicals, such as carnosic acid, showed 
inhibitory effects on MDR1 [46]. Soymilk and miso significantly induced MDR1 in an animal study 
[47]. Bioinformatic evidences showed that resveratrol (red currant, red wine) could act against MDR1, 
and that apigenin, biochanin A (peanut, soy bean), genistein, glycyrrhizin, naringenin, quercetin, and 
resveratrol act against MRP2 [11]. Data is summarized in Table 2. 
Table 1. Enteric and hepatic transporters of the solute carrier (SLC) superfamily that are targeted by 
food bioactive compounds. 
Transport 
Enzyme 
Food Bioactive Compound Reference 
OATP1A2 
- grapefruit compounds 
- naringin, hesperidin 
- apigenin, kaempferol, quercetin 
- [24],[27],[28],[30],[31] 
- [25] 
- [32] 
OATP1B1 
- naringenin, naringin, quercetin, daidzein, genistein, glycyrrhizin, 
caffeine 
- [11] 
OATP1B3 
- apigenin, kaempferol, quercetin, naringenin, naringin, rutin 
- naringenin, naringin, quercetin, daidzein, genistein, glycyrrhizin, 
caffeine 
- [33] 
- [11] 
 
OATP2B1 
- grapefruit, orange, and apple compounds 
- apigenin, kaempferol, quercetin, naringenin, naringin, rutin 
- naringenin, naringin, quercetin, daidzein, genistein, glycyrrhizin, 
caffeine 
- [26–29],[31] 
- [33] 
- [11] 
 
OCT1 - caffeine - [11] 
OATP = Organic Anion Transporting Polypeptides, OCT = Organic Cation Transporters. 
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Table 2. Enteric and hepatic transporters of the ATP-binding cassette (ABC) superfamily that are 
targeted by food bioactive compounds. 
Transport 
enzyme 
Food bioactive compound Reference 
MDR1 
- grapefruit, orange, tangerine, bitter melon compounds, diosmin, nobiletin 
- Welsh onion compounds 
- Ginseng compounds 
- sesamin, ginkgolic acid, glycyrrhetinic acid, glabridin 
- piperine 
- carnosic acid 
- soybean, dokudami, soymilk, and miso 
- resveratrol 
- [35–38],[40] 
- [36] 
- [42] 
- [43],[44] 
- [45] 
- [46] 
- [36],[47] 
- [11] 
MRP1 
- nobiletin 
- sulforaphane 
- glycyrrhetinic acid 
- [40] 
- [41] 
- [43] 
MRP2 
- grapefruit and orange compounds, naringenin sulforaphane 
- ginkgo compounds 
- apigenin, biochanin A, genistein, glycyrrhizin, 
- quercetin, resveratrol 
- [35],[11] 
- [41] 
- [44] 
- [11] 
BCRP bergamottin, tangeretin, nobiletin - [39] 
MDR1 = multidrug resistance protein 1, MRP1 = multidrug resistance-associated protein 1, MRP2 = 
multidrug resistance-associated protein 2, BCRP = breast cancer resistance protein. 
4.1.2. Food Interference with Enteric and Hepatic Metabolism 
Grapefruit is known as an inhibitor of both intestinal CYP3A4 and CYP1A2, thus causing an 
increased Cmax and AUC [24], with more risk for side effects/adverse outcomes. Grapefruit juice also 
proved to have an in vitro inhibitory potential on hepatic microsomal subfamily CYP3A [48], whose 
gene locus includes A4, A5, A7, and A43 members. This food-drug interaction was ascribed to 
different grapefruit constituents, such as furanocoumarins (bergamottin, bergapten), and flavonoids 
(e.g. naringin, naringenin, quercetin, and kaempferol) [49]. Bioinformatic studies confirmed that 
kaempferol, bergapten, naringenin, quercetin, tangeretin, and taxifolin (sweet orange, Mexican 
oregano) could interact with CYP3A4 [11]. In humans, quercetin inhibited CYP1A2 function, but 
enhanced CYP2A6 and NAT activity [50]. Ethanol is known to induce CYP2E1 [51]. Casticin 
(chasteberry—Vitex agnus-castus L.) and resveratrol were shown to interfere in vitro with both 
CYP3A4 and CYP2C9 [52]. Resveratrol activity against CYP3A4 was confirmed by bioinformatic 
approaches [11]. Resveratrol was non-competitive reversible inhibitor of CYP2E1 in rat and human 
liver cells [53]. Cranberry (Vaccinium macrocarpon A.) was involved in the possible potentiation of 
warfarin anticoagulation, as its content of anthocyanins, flavonols, proanthocyanidins, and phenolic 
acid derivatives was associated with the in vitro inhibition of CYP3A and CYP2C9 [54], but relevant 
pharmacokinetic interactions were excluded [55]. Conversely, significant clinical effects were caused 
by grapefruit and Seville orange juices [28]. Same food components of grapefruit juice are present in 
other foods, such as pomegranate (Punica granatum L.) and black mulberry (Morus nigra L.), thus 
accounting for some time- and concentration-dependent inactivation of hepatic CYP3A [48]. 
Conversely, an animal study suggested that both pomegranate and grapefruit components could act 
primarily on enteric, but not hepatic, subfamily CYP3A [56]. Intestinal effects of pomegranate juice 
were also confirmed by the increase AUC of tolbutamine in rats [57]. Epicatechin gallate (green tea, 
peppermint—Mentha × piperita L., common grape—Vitis vinifera L.) and tangeretin showed an in vitro 
potent inhibition of subfamily CYP1A in human liver microsomes [58], but tangeretin failed to have 
appreciable clinical effects [59]. Epicatechin gallate was reported to have bioactivity also against 
CYP3A4 [11]. Apple juice extract inhibited the catalytic activity of CYP1A1[60]. Sulforaphane induced 
the phase I bioactivating enzyme CYP1A1 [61], but reduced the expression of CYP3A4 [62]. The 
enzymes CYP1A2, CYP3A, and CYP2C11 are involved in caffeine metabolism [63], and theophylline 
acted on CYP1A2 as substrate inhibitor [51]. Theobromine (cocoa powder, coffee) may interfere with 
CYP3A4 [11]. In rats, diallyl disulphide from soft-necked garlic (Allium sativum L.) and piperine 
induced CYP1A1, CYP1A2, CYP2B1, CYP2B2. CYP2E1 was inhibited by diallyl disulphide and 
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induced by piperine. CYP3A4 was agonized by diallyl disulphide and by glycyrrhizin [64], but 
inhibited by piperine [45]. Diallyl disulphide was confirmed to be substrate of CYP3A4 [11]. Liquorice 
also induced CYP1A2 in vivo [65], and most members of CYPs [4]. Tomatoes (Solanum lycopersicum 
L.) and tomato-based products, such as ketchup, contain numerous phytochemicals, of whom 
lycopene is the best known. In rats, lycopene supplementation increased hepatic CYP2E1 [66]. 
Capsaicin, and ellagic acid (chestnut, blackberry, black raspberry) were reported to strongly inhibit 
in vitro CYP2A2, 3A1, 2C11, 2B1, 2B2 and 2C6 [67], with possible induction of CYP1A2 [68]. Capsaicin 
may be also substrate of CYP3A4 [11]. Hesperetin (lime, sweet orange) selectively inhibited human 
CYP1A1 and CYP1B1 [69], and is substrate also of CYP3A4 [11]. Soymilk and miso significantly 
induced CYP3A4 in an animal study [47]. Other than the abovementioned food components, 
bioinformatic studies showed different molecules to potentially interact with CYP3A4: 6-shogaol 
(ginger—Zingiber officinale R.), apigenin, biochanin A, caffeic acid (common verbena—Verbena 
officinalis L., tarragon, sweet basil, common thyme—Thymus vulgaris L.), curcumin, daidzein, 
diosgenin (fenugreek—Trigonella foenum-graecum L., carrot), estragole (anise—Pimpinella anisum L., 
fennel—Foeniculum vulgare M., sweet basil, tarragon), galangin (Mexican oregano), genistein, geraniol 
(common grape, black walnut—Juglans nigra L., common thyme, carrot), harmine, luteolin (Mexican 
oregano, globe artichoke—Cynara cardunculus var. Scolymus L., thyme, sage, anise, angelica—
Angelica keiskei I., broccoli), myricetin (common walnut, fennel, European cranberry, blackcurrant, 
black crowberry, Romaine lettuce—Lactuca sativa var. Longifolia L., highbush blueberry, strawberry), 
pyrocatechol (Arabica coffee), rutoside, safrole (nutmeg, sweet basil, rosemary), sesamin, and 
xanthotoxin (parsnip, parsley) [11]. In a clinical trial, charcoal-broiled meat induced CYP1A enzymes 
in the liver and small intestine of healthy volunteers [70]. Decreased CYP1A2 activity and increased 
CYP2A6 activity was displayed in women by genistein [71]. Genistein may be also substrate of 
CYP3A4 [11]. Watercress inhibited subfamily CYP2E1 and increased AUC of a substrate of the CYP 
in a clinical trial [72]. In a clinical trial, CYP1A2 activity was concluded to be increased by an enriched-
brassica diet, but decreased by an enriched-apiaceous diet (dill, celery, parsley, parsnip—Pastinaca 
sativa L.) [73]. The parsnip constituent imperatorin and the parsley component isopimpinellin may 
have activity against CYP3A4 [11]. Resveratrol was shown to increase Cmax, AUC, half-life, and 
decrease the elimination rate constant of substrates of CYP2C9 [74] and CYP2E1 [75] in healthy 
volunteers through an inhibitory mechanism. Bioinformatic approaches reported that CYP1A2 is 
targeted by apigenin, galangin, hesperetin, isorhamnetin (green bell pepper, dill, fennel, chives, 
tarragon), kaempferol, luteolin, naringenin, pinocembrin, and quercetin [11]. Furthermore, 
bergapten, furanocoumarin, and xanthotoxin can act against CYP2A6, 2B6. Moreover, apigenin, 
bergapten, biochanin A, capsaicin, curcumin, daidzein, dihydrocapsaicin, ellagic acid, furocoumarin 
(fig, parsley), galangin, genistein, hesperetin, kaempferol, luteolin, myricetin, naringenin, nicotine, 
pinocembrin, quercetin, resveratrol, sesamin, and xanthotoxin are substrates of CYP2C19 [11]. 
Apigenin, bergapten, biochanin A, caffeic acid, capsaicin, curcumin, daidzein, dihydrocapsaicin, 
ellagic acid, furocoumarin, galangin, genistein, hesperetin, kaempferol, luteolin, myricetin, 
naringenin, quercetin, resveratrol, and sesamin have activity against CYP2C9 [11]. The following 
phytochemicals were reported to have activity against CYP2D6: 6-shogaol, apigenin (marjoram, 
parsley, Chinese cabbage), bergapten (anise, fig, parsnip, parsley, celery stalks, grapefruit), β-
sitosterol (cherimoya—Annona cherimola L., canola, sesame, pistachio, common buckwheat), 
capsaicin, curcumin (turmeric, curry powder), daidzein, dihydrocapsaicin, formononetin (soy bean), 
galangin, harmine, hesperetin, kaempferol, luteolin, myricetin, pinocembrin (Mexican oregano), 
quercetin, resveratrol, phytoserotonin, sesamin (sesame seeds), and xanthotoxin [11]. Data is 
summarized in Table 3. 
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Table 3. Enteric and hepatic metabolizing enzymes of phase I that are targeted by food bioactive 
compounds. 
Metabolizing 
Enzyme 
Food bioactive compound Reference 
CYP1A 
- apigenin, apple, caffeine, capsaicin, charcoal-broiled meat, diallyl 
disulphide, ellagic acid, epicatechin gallate, esperetin, galangin, 
genistein, grapefruit, hesperetin, isorhamnetin, kaempferol, 
liquorice compounds, luteolin, naringenin, pinocembrin, piperine, 
quercetin, sulforaphane, tangeretin, teophillyne 
- [11],[24],[50],[51],[58],[60],[61], 
[63–65], [68–71],[73] 
CYP1B - hesperetin - [69] 
CYP2A 
- bergapten, capsaicin, ellagic acid, furanocoumarin, genistein, 
quercetin, xanthotoxin 
- [11],[50],[67],[71] 
CYP2B 
- bergapten, capsaicin, diallyl disulphide, ellagic acid, 
furanocoumarin, piperine, xanthotoxin 
- [11],[64],[67] 
CYP2C 
- apigenin, bergapten, biochanin A, caffeic acid, caffeine, capsaicin, 
casticin, cranberry, curcumin, daidzein, ellagic acid, galangin, 
genistein, hesperetin, kaempferol, luteolin, myricetin, naringenin, 
nicotine, pinocembrin, quercetin, resveratrol, sesamin, 
xanthotoxin. 
- [11],[52],[54],[63],[67],[74] 
CYP2D 
- 6-shogaol, apigenin, bergapten, β-sitosterol, capsaicin, curcumin, 
daidzein, formononetin, galangin, harmine, hesperetin, 
kaempferol, luteolin, myricetin, pinocembrin, quercetin, 
resveratrol, serotonin, sesamin, xanthotoxin 
- [11] 
CYP2E 
- diallyl disulphide, ethanol, lycopene, piperine, resveratrol, 
watercress compounds 
- [51],[53],[64],[66], [72],[75] 
CYP3A 
- 6-shogaol, apigenin, bergamottin, bergapten, biochanin A, black 
mulberry, caffeic acid, caffeine, capsaicin, casticin, curcumin, 
daidzein, diallyl disulphide, diosgenin, ellagic acid, estragole, 
galangin, epicatechin gallate, genistein, geraniol, glycyrrhizin, 
harmine, hesperetin, imperatorin, isopimpinellin, kaempferol, 
luteolin, myricetin, naringenin, naringin, piperine, pomegranate, 
pyrocatechol, quercetin, resveratrol, rutoside, safrole, sesamin, 
sulforaphane, tangeretin, taxifolin, theobromine, xanthotoxin 
- [4],[11],[24],[28],[45], 
[47–49],[52],[54], [56], 
[57],[62–64], [67] 
CYP = Cytochrome P450 enzyme. 
Concerning phase II enzymes, an in vitro study showed DT-diaphorase activity to be increased 
by watercress, garden cress, and mustard (Sinapsis alba L.), whereas UGT activity was shown to be 
augmented by garden cress and mustard, with a further agonist activity on NAT by mustard [76]. In 
humans, NAT activity was also enhanced by quercetin [50]. Milk thistle (Silybum marianum L.), the 
green tea catechin epicatechin gallate, saw palmetto (Serenoa repens JKS), cranberry, quercetin, and 
kaempferol inhibited in vitro different members of the UGT family of enzymes in liver microsomes 
[77]. Bioinformatic studies reported (+)-Catechin, apigenin, ergosterol (common wheat), galangin, 
menthol, naringenin, carvacrol (pot marjoram, common thyme, black walnut, winter savory), 
diosgenin, eugenol (cloves, allspice—Pimenta dioica L., carrot), linalool (spearmint, coriander, 
common thyme, winter savory, cardamom, sweet basil, sweet bay—Laurus nobilis L., orange mint—
Mentha citrate E.), naringin (rosemary, grapefruit/pomelo hybrid, grapefruit, pomelo—Citrus maxima 
M), quercetin, tea polyphenol, borneol (common sage, cardamom, rosemary, pot marjoram, common 
thyme, spearmint, winter savory), citronellol (ginger, sweet basil, winter savory), ethinyl estradiol 
(cloves, cardamom, ginkgo, nuts, nutmeg, star anise, ginger, Ceylon cinnamon), shikimic acid 
(mammee apple—Mammea americana L.), and caproic acid (milkfat, butter, cheese, cream, coconut) to 
be substrates of different UGTs [11]. The polyphenol punicalagin from pomegranate was able to 
inhibit enteric SULT, likely further affecting the availability of drugs [78]. Sulforaphane induced the 
activity of phase II drug detoxificating enzymes DT-diaphorase, GST [79], and SULT [80]. Of note, by 
comparing gene expression signatures of different foods and drugs, broccoli was shown to have the 
highest number of connections with drugs [11]. The induction of hepatic SULT was also reported for 
asparagus, eggplant, cauliflower, celery, carrot, and potato [80]. EPH and GST were increased in mice 
by freeze-dried soya bean, Brussels sprout, cauliflower, and onion [81]. Data is summarized in Table 
4. 
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Table 4. Enteric and hepatic metabolizing enzymes of phase II that are targeted by foods or relative 
compounds. 
Metabolizing 
Enzyme 
Food/Bioactive Compound Reference 
SULT 
- punicalagin 
- sulforaphane, asparagus, eggplant, cauliflower, celery, 
carrot, and potato compounds 
- [78] 
- [80] 
 
UGT 
- garden cress and mustard 
- milk thistle, epicatechin gallate, saw palmetto, 
cranberry, quercetin, kaempferol 
- (+)-catechin, apigenin, ergosterol, galangin, menthol, naringenin, 
carvacrol diosgenin, eugenol linalool naringin quercetin, tea 
polyphenol, borneol citronellol ethinyl estradiol shikimic acid, 
caproic acid 
- [76] 
- [77] 
 
 
- [11] 
 
 
DT-diaphorase 
- watercress, garden cress, mustard 
- sulforaphane 
- [76] 
- [79] 
EPH - soya bean, Brussels sprouts, cauliflower, and onion - [81] 
GST 
- sulforaphane 
- soya bean, Brussels sprouts, cauliflower, onion 
- [79] 
- [81] 
NAT 
- quercetin 
- mustard 
- [50] 
- [76] 
SULT = Sulfotransferases, UGT = UDP-glucuronosyltransferases, DT-diaphorase = NAD(P)H:quinone 
oxidoreductase, EPH = Epoxide Hydrolases, GST = Glutathione S-transferases, NAT = N-
acetyltransferases. 
4.2. Post-Systemic Interactions 
Food-drug interactions that happen after the entry into systemic circulation are part of post-
systemic interactions, comprising plasma protein interactions, and have rather similar interferences 
with proteins or metabolizing enzymes for tissue penetration or metabolism, respectively. Of note, 
both pre- and post-systemic metabolisms are also indirectly influenced by blood delivery through 
the hepatic portal vein, which is increased by the splanchnic blood flow associated to the presence of 
food. 
4.2.1. Food Interference with Blood Transport 
Drugs may freely circulate in blood or can be bound to serum proteins, and possible food-drug 
interactions occur at the level of blood transport. These types of interactions were mostly studied for 
anticonvulsants, which can be displaced from albumin-binding by fat emulsions of co-administered 
parenteral nutrition formula [82]. Serum albumin is known to bind a large number of molecules, 
including caffeine. In particular, polyphenols were shown to interfere with drug pharmacokinetics 
by acting on albumin-binding, which may ultimately result in increased drug uptake and/or 
elimination. In vitro displacement of albumin site II (in subdomain IIIA of naproxen) was shown for 
resveratrol and casticin, but no interference with site I (in subdomain IIA of warfarin-azapoprazone) 
was shown [52]. Salvianolic acid B and rosmarinic acid (Salvia miltiorrhiza B.) were reported to bind 
to bovine serum albumin through interaction with subdomain IIA [83], with salvianolic acid B being 
able to deeply interfere with warfarin subdomain in the human counterpart [84]. However, even if 
polyphenols were shown to form stable complexes with serum albumin, very small structural 
conformational changes may occur, thus not significantly displacing drugs. Moreover, different 
albumin binding sites and affinities for food components [85] may increase the uncertainty for 
relevant food-drug interactions. A partial albumin unfolding was reported upon binding with 
curcumin or genistein [86], but no significant perturbation for quercetin [87] binding. 
4.2.2. Food Interference with Renal and Brain Transport, and Post-Systemic Metabolism 
OCTs contribute to the permeability of the blood–brain barrier, whereas the members of organic 
anion transporting polypeptide (OATP1A4 and OATP1A5) and organic anion transporter (OAT3) 
families are involved in the efflux of organic anions from the CNS. OATs are mainly responsible for 
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renal tubular secretion from blood to urine, such as OAT1 and OAT3 on the basolateral side of the 
membrane, but also renal reabsorption from urine to blood, such as OAT4 on the apical side of the 
membrane [88]. ABC transporters are highly expressed in the endothelial cell surface of the blood 
brain barrier (BBB), choroid plexus epithelial cells [89], and renal proximal tubule [34]. The 
bioavailability for some acidic or basic drugs that rely on a tubular passive permeation mechanism is 
affected by changes of luminal pH. Dietary proteins/protein food tend to make urine more acidic [90], 
thus rendering weakly acidic drugs better reabsorbed. Conversely, if urine is alkaline, then weak 
bases tend to be more easily reabsorbed. Components of licorice were shown to be substrates of OAT1 
[91]. The inhibition of efflux mechanisms of MDR1, MRP4, or BCRP in the BBB would cause an 
increase in the concentration of substrates in the CNS, as was observed for MDR1 and antipsychotics 
[92]. Conversely, the induction of ABC transporter expression would decrease central bioavailability 
of substrates, as was reported for MDR1 and fexofenadine in rats fed long-term with ginseng [42]. 
ABC secretory transporters in kidneys mainly comprise MDR1 for organic cations and MRP2 or 
MRP4 for organic anions. In rat renal proximal tubules, isothiocyanates inhibited BCRP and caused 
an increase of AUC of the substrate in rat renal proximal tubules [93]. Lycopene was shown to inhibit 
in vitro post-systemic bio-activating CYP1A1 and CYP1B1, with a concomitant increased microsomal 
detoxifying UGT activity [94]. In conclusion, dysfunction of both P-glycoprotein and BCRP exhibits 
synergy on the increase in the brain-to-plasma concentration ratio of the common substrates. 
Evidence of post-systemic pharmacokinetic interactions came from bioinformatic studies: apigenin, 
quercetin, naringenin, resveratrol and nicotinic acid were found to have the strongest binding 
affinities with drug ADME proteins [11]. 
5. Pharmacodynamic Interactions 
A variety of pharmacodynamic interactions has been observed in preclinical, clinical, but also 
bioinformatic studies, which consider the predicted bioactivity profile, as the chemical space of food 
components was linked with drug target space. Foods that contained the most interfering 
components with drug targets, such as receptors, were found to be ginger, camellia tea, poppy seed, 
beansprout, strawberry, tomato, swede, fennel, celery, licorice, guava, sugar-pea, mango, maize, 
turnip, rice, and avocado. Apparently, food components showed a main bioactivity towards proteins 
involved in signal transduction [11]. Specifically, the food-drug interactome map underscored several 
pharmacodynamic food-drug interactions. Naringenin can target aromatase, and kaempferol has a 
high affinity for the epidermal growth factor receptor. Phytoserotonin (sea buckthorns—Hippophae 
rhamnoides L., bananas, chicory, Chinese cabbage, coffee powders, green coffee bean, green onion, 
hazelnut, kiwi, lettuce, nettle, paprika, passion fruit, pawpaw, pepper, pineapple, plantain, plum, 
pomegranate, potato, spinach, strawberry, tomato, velvet bean, wild rice, sunflower, potato, and 
tomato) [2], interacts strongly with 5-hydroxytryptamine receptors. P-hydroxybenzoic acid (coconut, 
currant, sprouted lentil, swede) binds strongly to carbonic anhydrase. Resveratrol was found to 
interfere with the estrogen receptor and prostaglandin G/H synthase 2, but also caffeic acid, daidzein, 
genistein, kaempferol, naringenin, quercetin, rutoside can act against estrogen receptors [11]. 
Acetylcholinesterase and cholinesterase are targets of quercetin, apigenin, galangin, kaempferol, 
luteolin, myricetin, rutoside, harmine, hesperetin, kaempferol, luteolin, myricetin, naringenin, 
rutoside, eriodictyol (Mexican oregano, lemon, marjoram, lemon balm—Melissa officinalis L.) [11]. 
Potential interactions with glutamate receptors were reported as glutamate/glutamic acid was 
described to be present in caviar, cheese, crackling, chips, dried cod, fermented beans, fish sauces, 
gravies, instant coffee powder, meats, miso, mushrooms, noodle dishes, oyster sauce, Parmesan 
cheese, ready-to-eat meals, salami, savory snacks, seafood, seaweeds, soups, soy sauces, spinach, 
stews, tomato, and tomato sauce [2]. Higenamine (custard apple) was reported to act on D(2) 
dopamine receptor and D(1A) dopamine receptor was found to be targeted by taxifolin, alpha-
aminoadipic acid (rye, wheat, broccoli, dill, chard), dihydrocapsaicin, myricetin, quercetin, and 
phytodopamine (chard, oat, red beetroot, but also aubergine, avocado, banana, common bean, apple, 
orange, pea, plantain, spinach, tomato, and velvet bean) [2]. β2 adrenergic receptor is targeted by 
liquiritin [11]. 
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6. Discussion 
For many years, CAM approaches have been introduced to improve human health, and their 
role has evolved from folk medicine to worldwide usage, according to different attitudes and 
regulatory aspects. However, a dark side of CAMs exists [95,96]. A diverse range of food compounds 
constantly interact with proteins involved in drug PK/PD profiles, starting from the absorption phase 
to possible alterations in clinical efficacy, with potential involvement in pharmacological 
refractoriness, side effects of drugs or unexpected adverse events. Although the amount of food 
bioactive compounds that needs to be consumed in order to interfere with a specific mechanism can 
be far from the usual exposure, the potential for additive interference of more than one molecule or 
during chronic intake should be considered. Bioinformatic approaches can account for that aspect 
[11]. For instance, authors interviewing a large cohort of neuropsychiatric patients reported that 
about 80% of subjects using CAMs initiated the use without informing their doctor [97]. Patients 
consider their use of CAMs not worthy of note, or they feel uncomfortable in admitting turning to 
non-traditional medicine remedies. Usage of CAMs may be hidden during first anamneses with 
doctors, being subsequently exposed only during follow-ups [9]. Hospitalized patients may 
encounter a higher risk of food-drug interactions during hospital standard of care, especially if not 
investigated [98]. Subjects with impaired hepatic, renal, or gastro–intestinal function may be more 
vulnerable, together with patients taking several medications for chronic conditions. More caution 
should be considered for food components that inhibit metabolizing enzymes or interfere with the 
metabolism of hydrophobic drugs, whose accumulation in adipose tissue and cellular phospholipid 
bilayers can be increased. If the therapeutic window is narrow, then food interference may easily 
cause a relevant clinical effect [13]. Conversely, dietary recommendations do not exactly satisfy 
individual needs and CAMs, such as dietary supplements, can fill the nutritional gap between needs 
and intakes, thus ameliorating the nutritional status or avoiding specific heath issues [99]. In parallel, 
food was enriched or fortified in order to avoid either natural impoverishment [100] or the impact of 
cooking methods on nutritional values [101]. CAM approaches can attain confident results if well 
managed, for instance protein-redistribution diet in Parkinson’s disease treated with levodopa [102], 
low day-to-day variability in dietary vitamin K during warfarin therapy [7], low-fat meals for oral 
chemotherapeutics [22], regular water and sodium intake with lithium [103], or low-tyramine diet 
with monoamine oxidase inhibitors [104]. 
Both positive and negative abovementioned results in clinical practice are due to the fact that 
foods and beverages affect the way medicines exert their effects through diverse mechanisms, which 
can be classified as pharmaceutical, pharmacokinetic, and pharmacodynamic food-drug interactions. 
This is tuned to give the broadest view to the readers by providing a comprehensive classification of 
the major site of food-drug interactions, as pharmaceutical interferences, blood protein disruptions, 
and direct pharmacodynamic interferences are usually disregarded [3-5, 13]. Furthermore, for the 
first time, evidence from bioinformatic approaches have been integrated with the literature data. 
Results are summarized in Table 5. Most of the data concerning food interference with drug 
metabolism comes from in vitro or animal studies, but preclinical models cannot be uniquely relied 
upon for predicting relevant human food-drug interactions, as large differences among species in the 
ability to metabolize xenobiotics exist. Moreover, in vitro evidence may be difficult to observe in 
humans, because of insufficient concentrations of causative food components at the drug active site. 
Pharmaceutical interactions for oral drugs may be avoided when preferring fasting. If a fed condition 
is required, health professionals should pay attention to the meal content of minerals, fiber, and 
macromolecules, such as proteins and lipids. Sometimes, a pharmaceutical interaction with food is 
needed in order reduce drug side effects [13]. Concomitant alcoholic beverage intake (wine, beer, 
spirits) is always forbidden, especially for modified-release systems that could encounter a rapid 
release known as alcohol-induced dose dumping [105]. 
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Under in vitro conditions, a high amount of food bioactive compound may target cellular 
transporters or metabolizing enzymes, while varying levels occur in animals or humans because food 
molecules are extensively metabolized. Therefore, a relevant preclinical interaction may be a non-
relevant clinical interaction. For example, few clinical effects were suggested when considering the 
interference of food components with plasma protein binding [106]. Food bioactive compounds 
bioavailability may be influenced by many factors, such as the luminal pH of the intestine [107], inter-
individual variabilities, hydrophobic properties of the food molecule [108], or even drugs themselves. 
In fact, drug metabolism can directly alter the same steps of food components kinetic profile, and 
some medications may cause gastrointestinal dismotility or diarrhea, thus indirectly affecting food 
component bioavailability. The compositions of commercial juices varies according to brand, lot, and, 
in the case of homemade juices, method of preparation [109]. Additionally, different parts of the same 
plant, such as the stem or fruits, may have very diverse compositions also depending on subspecies 
and variety of plants, cultivar and ecotype, chemotype, soil and nourishment, geographical location, 
environmental impact during plant growth, seasons of growth and harvest, weather and climate 
changes, and agricultural practices [2]. Clinical trials showed significant pharmacokinetic 
interactions, whose practical consequences on pharmacological response were shown to vary. Of 
note, only grapefruit juice appeared to give the most promising clinical data, probably due to its now-
dated interest. However, fruits from the Citrus genus, such as Seville orange or pomelos, may have 
the same effect as grapefruit juice and their consumption should be avoided if taking medicines that 
interact with grapefruit juice. Still, to study other suggested food-drug interactions in human clinical 
trials would be preferred in order to prevent their interactions before they are observed in daily 
practice. 
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Table 5. Types of food-drug interactions, targets, and food components that can interfere with drug pharmacokinetic/pharmacodynamic profiles. 
Types of Food-Drug 
Interactions 
Targets Food Components 
a. Pharmaceutical   
 - solubilization, stabilization, and dissolution properties 
- alcohol (wine, beer, spirits), capsaicin, cations from milk and dairy products, insoluble 
fibers (cellulose, bran), soluble fibers (pectin, glucomannan, psyllium, guar gum), lipids, 
phytoserotonin, proteins 
b. Pharmacokinetic   
Pre-systemic - enteric and hepatic transporters of SLC and ABC 
- 1-monopalmitin, apigenin, bergamottin, biochanin A, caffeine, carnosic acid, daidzein, 
genistein, ginkgolic acid, glabridin, glycyrrhetinic acid, glycyrrhizin, hesperidin, 
kaempferol, naringenin, naringin, nobiletin, piperine, quercetin, resveratrol, rutin, 
sesamin, soymilk and miso components, sulforaphane, tangeretin, tangeretin 
 
- enteric and hepatic metabolizing enzymes of CYPP450 families 
and phase II enzyme reactions, such as SULT, UGT, DT-
diaphorase, EPH, GST, NAT 
- (+)-catechin, 6-shogaol, apigenin, asparagus components, bergamottin, bergapten, 
biochanin A, black mulberry components, borneol, caffeic acid, caffeine, caproic acid, 
capsaicin,, carrot components, carvacrol, casticin, charcoal-broiled meat, citronellol, 
cranberry components, curcumin, daidzein, diallyl disulphide, dihydrocapsaicin, 
diosgenin, eggplant components, ellagic acid, epicatechin gallate, ergosterol, estragole, 
ethanol, ethinyl estradiol, eugenol, formononetin, freeze-dried soya bean components, 
furanocoumarin, furocoumarin, galangin, genistein, geraniol, glycyrrhizin, harmine, 
hesperetin, imperatorin, isopimpinellin, isorhamnetin, kaempferol, linalool, luteolin,, 
lycopene, menthol, milk thistle components, mustard, myricetin, naringenin, naringin, 
nicotine, onion components, phytoserotonin, pinocembrin, piperine, pomegranate 
components, potato components, punicalagin, pyrocatechol, quercetin, resveratrol, 
rutoside, safrole, saw palmetto components, sesamin, shikimic acid, soymilk and miso 
components, sulforaphane, tangeretin, taxifolin, tea polyphenols, theobromine, 
theophylline, watercress and garden cress components, xanthotoxin, β-sitosterol 
Post-systemic 
- transporters, such as albumin, SLC, and ABC. Metabolizing 
enzymes of CYPP450 families and phase II enzyme reactions, 
such as UGT 
- apigenin, caffeine, casticin, curcumin, genistein, ginseng, isothiocyanates, licorice, 
lycopene, naringenin, nicotinic acid, proteins, quercetin, resveratrol, resveratrol, 
rosmarinic acid, salvianolic acid B 
c. Pharmacodynamic   
 
- aromatase, epidermal growth factor, 5-hydroxytryptamine, 
carbonic anhydrase, estrogen, prostaglandin G/H synthase 2, 
acetylcholinesterase, cholinesterase, glutamate receptors, D(2) 
and D(1A), and β2 adrenergic receptors 
- α-aminoadipic acid, apigenin, caffeic acid, daidzein, dihydrocapsaicin, eriodictyol, 
galangin, genistein, glutamate/glutamic acid, harmine, hesperetin, higenamine, 
kaempferol, liquiritin, luteolin, myricetin, naringenin, P-hydroxybenzoic acid, 
dopamine, phytoserotonin, quercetin, resveratrol, rutoside, taxifolin 
SLC = Solute Carrier, ABC = ATP-Binding Cassette, CYP450 = Cytochrome P450, SULT = Sulfotransferases, UGT = UDP-Glucuronosyltransferases, 
DT-diaphorase = NAD(P)H:quinone oxidoreductase, EPH = Epoxide Hydrolases, GST = Glutathione S-transferases, NAT = N-acetyltransferases
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A complete patient education should focus on the possible presence of the warning “do not 
crush”: if ignored by the patient, pharmaceutical interactions with food would be more likely to 
happen for special formulations, such as those that are enteric-coated or slow-release in nature. It 
should be impressed on patients not to swallow drugs with alcohol, drink alcohol after drug 
ingestion, or take medicine after alcohol consumption [110]. However, concomitant abstention from 
alcoholic beverages during drug administration should be further extended to chronic abstention, as 
an additive action on diverse pharmacokinetics aspects was noted, other than the well-known 
alcohol-induced dose dumping phenomenon. Indeed, for chronically ill subjects it would be hard to 
totally exclude alcohol from dietary habits because light alcoholic beverages, such as red wines, are 
considered part of the much-advertised Mediterranean diet. If a bioactive food compound acted 
uniquely on metabolizing enzymes, drugs that are a substrate of the same CYP would be poorly 
metabolized and would remain in the body for longer periods of time. Induction of CYPs that carry 
out the oxidation of substrates with the production of activated oxygen, for instance the case of the 
uncoupled CYP3A4 reaction, could lead to the rise of oxidative stress. Lack of relevant clinical 
evidence may be related to the short phase of food exposure, usually a few weeks for trials [55]. In 
fact, chronic and not-occasional consumption of a specific food may cause a relevant food-drug 
interaction, as interference with target proteins from a single exposure may last only a few days [56]. 
Evidence from animal studies has confirmed the minor affection of single dose exposure of a food 
bioactive compound, compared to repeated administrations [111]. Other than red wine, bioinformatic 
studies showed that most of the food molecules that bind to human proteins are also very common 
in the Mediterranean diet and in turn difficult to avoid. However, the main limitation of bioinformatic 
approaches is that even if a food component was found to be active against a drug target, it is not 
known if this interaction would cause an interference with the drug-binding mechanism [11]. What 
should be pointed out, however, is that the bioinformatic approach was able to identify sub-networks 
of foods that contain molecules interacting with specific proteins, possibly accounting for these 
aspects when medicines targeting the same proteins are prescribed. 
7. Conclusion 
To investigate individual variance, during the past few years research has turned to 
pharmacogenomics, thus pursuing the much-desired tailor-made therapy. However, even before 
reaching these levels of perfection, it is necessary to take a step backwards, as the optimization of 
drug compliance and the precise avoidance of food-drug interactions has not yet been reached. 
Knowledge of any nutraceutical or phytochemical residue, additive, contaminant, adulteration with 
non-declared ingredient, and dietary neurotransmitter is the condition sine qua non there is no well 
aware nutrition, and would provide a missing link for obtaining a holistic view in clinical practice. 
Then, it is important to have good knowledge about the type and number of binding sites that a 
certain food component will interact with on a given protein because this information would allow 
health professionals to estimate the degree of interference. Because of the opportunity to positively 
exploit interferences between foods and drug mechanisms, health professionals should be aware of 
relevant interactions in order to optimize the therapeutic effects of both prescribed and over-the-
counter drugs. Figure 1 summarizes the major sites of food-drug interactions. For example, to prevent 
multidrug resistance, inhibitors of efflux transporters are considered a useful therapeutic approach, 
and food components may be considered more promising candidates for sensitizing patients to a 
particular drug [112]. It would be necessary to promptly make a change in a patient’s diet in order to 
increase therapeutic efficacy according to the disease category, such as for cancer and cardiovascular, 
musculoskeletal, or neurological diseases. Information about food-drug interactions should always 
be included in patient and caregiver education, starting with historical indications to avoid 
concomitant intake of alcohol or caffeine [9], but also integrating new recommendations about 
optimal timing, meal composition, and intake or avoidance of food bioactive compounds. 
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Figure 1. Major sites of food-drug interactions. SLC = solute carrier proteins, ABC = ATP-binding 
cassette proteins, CYP = cytochrome P450. 
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